Bristol-Myers's Opdivo (nivolumab) Receives FDA Priority Review for 2L+ Patients with SCLC in ~20 yrs
Shots:
- Approval is based ongoing Ph 1/2 CheckMate-032- study is assessing 245 patients in two arms Opdivo vs platinum based therapy
- CheckMater-032 Results: ORR:12% (13/109); PR: 11% (12/109); CR: 0.9% (1/109); mDOR: 17.9 mos; SAE: 45%
- Approved dose for Opdivo for SCLC is 240mg IV Q2W until disease progression or unacceptable toxicity
Ref: Bristol-Myers | Image: NYSE
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
